Citi Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

Tip Ranks
2025.12.04 00:47
portai
I'm PortAI, I can summarize articles.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals, setting a price target of $117.80. The shares closed at $20.66. Nochomovitz, who covers the Healthcare sector, has an average return of 4.7% and a 39.51% success rate. Apellis has a Moderate Buy consensus with a price target of $38.27.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Apellis Pharmaceuticals on December 2 and set a price target of $117.80. The company’s shares closed yesterday at $20.66.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Nochomovitz covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Neurocrine, and ACADIA Pharmaceuticals. According to TipRanks, Nochomovitz has an average return of 4.7% and a 39.51% success rate on recommended stocks.

Apellis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $38.27.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer